Franklin Biotechnology Discovery Fund Class A (FBDIX)

160.40
Net Asset Value
-0.22%
1 Day
+6.67%
Year-to-Date
Overall Morningstar Rating
Health
Style or Category
5.75
Sales Expenses
1.06%
Expense Ratio
Above Average
Morningstar Risk Rating™
Investment Objective The investment seeks capital appreciation. Under normal market conditions- the fund invests at least 80% of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies- the fund may also invest up to 20% of its net assets in equity or debt securities of any type of issuer. It is non-diversified.

Performance

1 month+4.85% 3 years-3.74%
3 months+3.79% 5 years+14.70%
1 year+6.54% Since inception+11.45%
Data through --

Peer Comparisonvs. Health

 FBDIXCategory
Performance 5-yr return+14.70%+14.29%
Expense ratio1.06%1.29%
Risk 5 year sharpe ratio0.600.90
Net assets$1.4B$3.0B
Average market cap$7.3B$28.5B
Average P/E--25.2
Portfolio turnover34%34%

There are thousands of mutual funds to choose from. Get Money Magazine’s picks in all major categories.

Fund Management and Purchase Info

Fund familyFranklin Templeton Investments
Fund manager & tenureEvan McCulloch / 20 Years
Minimal initial investment$1,000.00
Minimum IRA investment$250.00

Holdings

U.S. stock91.87%
International stock5.52%
Cash2.33%
Fixed income0.28%
Other0.00%
Top 5 Sectors
Portfolio weighting
Healthcare 100.00%
Business service 0.00%
Consumer goods 0.00%
Consumer service 0.00%
Energy 0.00%
Top 10 Holdings
Portfolio weighting
ALXN Alexion Pharmaceuticals Inc7.10%
CELG Celgene5.95%
BIIB Biogen5.02%
VRTX Vertex Pharmaceuticals Inc4.95%
ILMN Illumina Inc4.42%
HRTX Heron Therapeutics Inc3.41%
BMRN Biomarin Pharmaceutical Inc3.14%
REGN Regeneron Pharmaceuticals3.12%
AMGN Amgen3.07%
GILD Gilead Sciences3.04%